The main problems encountered with anti-CTLA-4 treatment are the resistance of advanced tumors, due to a strong tumor-induced T cell tolerance, which may be partially PD-1 pathway mediated, and a lack of tumor specificity (121). Here, PDCD1 is linked to neoplasm.